Infliximab (Remicade)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Infliximab

What it is

Infliximab is a biologic medicine, a monoclonal antibody that binds and neutralises TNF-alpha, a key signal of inflammation. Given by drip every few weeks, it is used for Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and psoriasis. It is sold as Remicade and as several biosimilars.

How genes come into it

As an antibody, infliximab is not broken down by drug-processing enzymes. Studies have looked for genes that predict who responds, such as variants in TNF itself and its receptors (TNFRSF1A, TNFRSF1B), and in the antibody receptors FCGR2A and FCGR3A. A notable finding is HLA-DQA1*05, linked to forming antibodies against infliximab, which can make it stop working. There is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Infliximab. Upload your DNA file to see which of these rows apply to you.

Rated evidence (21 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

TNFRSF1B rs1061622: Level 3. Efficacy: Rheumatoid arthritis. 4.

PTPRC rs10919563: Level 3. Efficacy: Rheumatoid arthritis. 2.

FCGR2A rs1801274: Level 3. Efficacy: Rheumatoid arthritis. 2.

FCGR3A rs396991: Level 3. Efficacy: Psoriasis. 2.

Response (110 findings)

Studies of how well it worked in people carrying a variant.

rs12081765: Allele G is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A.

rs1350948: Allele A is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G.

rs2097432: Genotypes CC + CT is associated with decreased response to infliximab in people with Crohn Disease as compared to genotype TT.

rs2097432: Genotypes CC + CT are associated with increased discontinuation of infliximab in people with Crohn Disease as compared to genotype TT.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Cimzia (TNF Inhibitors)

Enbrel (TNF Inhibitors)

Humira (TNF Inhibitors)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com